Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment Patterns and Associated Outcomes in Chronic Phase (CP) Chronic Myelogenous Leukemia (CML) Patients Who Fail Imatinib 400 mg Daily

NCT01394666 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT01394666
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01394666 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment Patterns and Associated Outcomes in Chronic Phase (CP) Chronic Myelogenous Leukemia (CML) Patients Who Fail Imatinib 400 mg Daily
Lead sponsor
Bristol-Myers Squibb
Phase
Observational
Overall status
Completed
Start date
May 31, 2011
Completion date
December 31, 2012
Enrollment
150 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia